IL-8RA CRISPR Activation Plasmid (h): sc-401645-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- IL-8RA CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- IL-8RA CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by IL-8RA CRISPR Activation Plasmid (h) and IL-8RA CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the CXCR1 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: IL-8RA Antibody (B-1): sc-7303
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IL-8RA CRISPR Activation Plasmid (h) | sc-401645-ACT | 20 µg | $397.00 |
Human CXCR1 encodes IL-8RA (CXCR1), a G protein-coupled receptor that binds the ELR+ CXC chemokine CXCL8/IL-8 to regulate neutrophil chemotaxis, firm adhesion, and activation. Ligand engagement triggers Gαi-dependent signaling with downstream PLCβ/Ca²⁺ flux, PI3K–AKT, MAPK/ERK, and small GTPase pathways that coordinate cytoskeletal remodeling, degranulation, and respiratory burst. CXCR1-driven leukocyte trafficking and inflammatory amplification are widely studied in mucosal immunity and tumor-associated inflammation, and dysregulated signaling has been implicated in chronic inflammatory disorders and cancer progression. As a cell-surface chemokine receptor, IL-8RA is also used as a marker and functional node in studies of myeloid biology and microenvironmental crosstalk.
IL-8RA CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous CXCR1 expression without altering the underlying DNA sequence.
IL-8RA CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the CXCR1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the CXCR1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous IL-8RA expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native CXCR1 locus and enabling the study of IL-8RA-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of IL-8RA pathway restoration in tumor cells with silenced or reduced CXCR1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.